Effectiveness of MiniMed 640G with SmartGuard® System for prevention of hypoglycemia in pediatric patients with type 1 diabetes mellitus

Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-term Randomized Controlled Trial in Adolescents With Type 1 Diabetes

“…This study highlights an almost twofold reduction in hypoglycemia exposure in children and adolescents with type 1 diabetes using PLGM during a 6-month, multicenter, randomized controlled home trial. These results support the findings of the in-clinic studies that used the investigational PLGM system (4-6) and the short-term observational studies and trials that used the MiniMed 640G pump with the SmartGuard function in children and adults (7)(8)(9)(10)(11)(12). In our study, both groups demonstrated a reduction in hypoglycemia, although the magnitude of reduction was greater with PLGM.…”

“…The next step has been the development of an algorithm that predicts impending hypoglycemia based on CGM and suspends basal insulin before the occurrence of hypoglycemia. The predictive low-glucose management (PLGM) system, the only commercially available sensor-integrated insulin delivery system, has been shown to reduce hypoglycemia in in-clinic conditions (4)(5)(6), in short-term outpatient observational studies (7)(8)(9)(10)(11), and recently in a 2-week randomized controlled trial (12). The important question as to whether the system is effective and safe in long-term use, and by inference in clinical practice, is however untested, especially as long-term CGM use has been challenging for many patients.…”

ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes

“…In the absence of patient interference, following pump suspension, the insulin infusion resumes after a maximum suspend period of 2 hours or earlier if the auto‐resumption parameters are met. PLGM reduced hypoglycemia under in‐clinic conditions and in short‐ and long‐term home studies. There was also no deterioration of glycemic control with the use of the system in a 6 month randomized controlled home trial …”

Long-term sensor-augmented pump therapy for neonatal diabetes mellitus: a case series

“…If adults caring for patients with NDM do not recognize hypoglycemia, treatment may be delayed. Although previous reports mentioned that SmartGuard Technology can prevent hypoglycemia in patients with type 1 DM, including children, we suggest that this system is particularly useful for patients with NDM who have difficulty detecting hypoglycemia ( 13 , 14 , 15 ).…”